My HPRA: Register

Updates and information for healthcare professionals

The HPRA provides information and updates related to the regulation of COVID-19 vaccines. Please click on the links below to download relevant documents.

Direct Healthcare Professional Communications

15 October 2021  VAXZEVRIA™/COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia (including immune thrombocytopenia) with or without associated bleeding
 
15 October 2021  COVID-19 Vaccine Janssen: Risk for immune thrombocytopenia (ITP) and venous thromboembolism (VTE) 
19 July 2021 COVID-19 Vaccine Janssen: Contraindication in individuals with previous capillary leak syndrome and update on thrombosis with thrombocytopenia syndrome 
16 July 2021   COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis
21 June 2021 VAXZEVRIA/COVID-19 Vaccine AstraZeneca - Important Safety Information from AstraZeneca: Contraindication in individuals with previous capillary leak syndrome
02 June 2021  VAXZEVRIA/COVID-19 Vaccine AstraZeneca - Important Safety Information from AstraZeneca: Risk of thrombosis in combination with thrombocytopenia – Updated information  

26 April 2021

COVID-19 Vaccine Janssen: link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia

13 April 2021

 

VAXZEVRIA / COVID-19 Vaccine AstraZeneca: link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia

24 March 2021

 

 COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia and coagulation disorders


Drug safety newsletters

August 2021  Drug Safety Newsletter Issue 104: PRAC recommendations and advice on rare adverse reactions associated with COVID-19 vaccines

April 2021

Drug Safety Newsletter Issue 103: COVID-19 Vaccine Janssen – EMA review of very rare cases of thrombosis in combination with thrombocytopenia following vaccination

March 2021

 

Drug Safety Newsletter Issue 102: COVID-19 Vaccine AstraZeneca – conclusion of EMA review of thromboembolic events following vaccination

February 2021

Drug Safety Newsletter Issue 101: Special Edition on COVID-19 Vaccines Safety Monitoring Activities


HPRA statements

20 April 2021

EMA Review of COVID-19 Vaccine Janssen

07 April 2021

EMA Review of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca)

18 March 2021

EMA Review of COVID-19 Vaccine AstraZeneca 

14 March 2021

COVID-19 Vaccine AstraZeneca 

18 February 2021

Opening Statement Department of Health Press Briefing 
18 January 2021 Opening Statement Department of Health Press Briefing